Stocks and Investing Stocks and Investing
Thu, January 2, 2020
Tue, December 31, 2019
Mon, December 30, 2019
Fri, December 27, 2019
Thu, December 26, 2019
Tue, December 24, 2019

Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $173 on, Dec 24th, 2019


Published on 2024-10-26 19:30:44 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $160 to $173 on, Dec 24th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $200 on, Monday, December 23rd, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $192 on, Friday, December 20th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Increased Target to $175 on, Friday, December 13th, 2019
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $167 on, Monday, November 18th, 2019
  • Whitney Ijem of "Guggenheim" Initiated at Strong Buy and Held Target at $183 on, Friday, November 1st, 2019

Contributing Sources